Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD126/IL-6R alpha/IL6R drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL6R ECD-Fc Fusion Protein (Classical Signaling) / Mutant Protein Human/Mouse/Cyno Orthologs Available. Sequence Verified. High Purity (>95% by SDS-PAGE). Endotoxin <1 EU/µg. HEK293 Expressed (Native Glycosylation). |
View IL6R Products |
| Gene Delivery | IL6R Lentivirus Premade Particles Full-length ORF with puromycin selection. For stable BaF3 or CHO cell line construction. Preserves conformation for internalization assays. |
View IL6R Products |
| Benchmark Ab | Anti-IL6R (Tocilizumab/Sarilumab Biosimilar Sequence) Recombinant human IgG1, CDR sequence matched. Positive control for blocking assays. |
View IL6R Products |
| Validator | IL6R siRNA Set (Triple-targeting) For knockdown verification in cell-based functional assays. Endotoxin controlled. |
View IL6R Products |
| Ligand | IL6 (Interleukin-6) High purity cytokine for competitive binding and classical/trans-signaling differentiation assays. |
View IL6 Products |
| Co-receptor | IL6ST (gp130) Signal-transducing subunit. Essential for functional reconstitution assays and specificity counter-screening. |
View IL6ST Products |
| Downstream | JAK1 Recombinant Protein Kinase domain for phosphorylation assays. High purity (>90%). |
View JAK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Classical vs. Trans-Signaling Differentiation | Soluble IL6R (sIL6R) and Membrane-bound IL6R ECD-Fc variants both available. Sequence verified to distinguish shedding versus expression. |
| gp130 Shared Subunit Specificity | IL6ST (gp130) Homolog Panel available for cross-reactivity screening against IL11, LIF, OSM, CNTF. |
| High-Concentration Subcutaneous Formulation | Aggregation-tested ECD-Fc proteins (>100 mg/mL theoretical stability data). Viscosity-compatible buffers. |
| Cynomolgus Toxicology Bridge | Human and Cyno IL6R proteins >95% purity with <0.05% cross-species sequence deviation in binding domains. |
| Immunogenicity (ADA) Assay Controls | Tocilizumab biosimilar antibody included as reference standard. Validated siRNA for specificity confirmation. |
Live IL6R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The IL6R (CD126) therapeutic landscape is transitioning from intravenous (IV) dominance to high-concentration subcutaneous (SC) formulations, driven by patient compliance demands. With Tocilizumab biosimilars now entering global markets, next-generation differentiation focuses on extended half-life and improved injection viscosity. Beyond rheumatoid arthritis, the target has gained critical traction in Cytokine Release Syndrome (CRS) management and CAR-T cell therapy adjuvant protocols, alongside emerging investigations in neuroinflammatory conditions (e.g., NMOSD) and giant cell arteritis. As the market matures, combination strategies with JAK inhibitors and the exploitation of trans-signaling versus classical signaling blockade represent the primary vectors for clinical innovation. Next-generation modalities include recycling antibodies with pH-dependent binding and bispecific antibodies targeting IL-6R and other inflammatory cytokines.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Roche (Tocilizumab), Sanofi/Regeneron (Sarilumab), Bio-Thera (Biosimilar) | Rheumatoid Arthritis, JIA, CRS | IL6/gp130 Competition Assay (Need high-purity IL6R & IL6ST proteins) |
| Biosimilar | Bio-Thera, Fresenius, Sandoz | Rheumatoid Arthritis, Giant Cell Arteritis | ADC Kinetics & Immunogenicity Panel (Need Tocilizumab reference Ab) |
| SC High-Concentration mAb | Roche (Subcutaneous Tocilizumab) | Autoimmune (Home Administration) | High-Concentration Stability/Viscosity Assay (Need aggregation-resistant ECD-Fc controls) |
| Recycling Antibody | Chugai, Roche | NMOSD | pH-dependent Binding Assay (Need high-quality Antigens for pH 6.0 vs 7.4 SPR) |
| Bispecific Antibody | Various | Complex Autoimmune | Heterodimer Validation (Need Cross-reactive Abs & Recombinant gp130) |
| Decoy Receptor (Fc-Fusion) | Concept Stage (Etarigcept-like dual targeting) | Multi-Cytokine Inflammation | Heterodimer Validation (Need IL6R-IL1R2 or IL6R-TNFR constructs) |
Molecular Differentiation & Assay Strategy
Affinity & pH-Dependent Binding
- Need: For next-generation recycling antibodies, high affinity at pH 7.4 (pM range) and rapid dissociation at pH 6.0 are required for extended half-life.
- Assay: pH-gradient SPR/BLI analysis measuring Kon and Koff at pH 7.4 vs pH 6.0.
- TarMart Advantage: High-purity IL6R ECD-Fc with native glycosylation (HEK293) ensures accurate binding kinetics.
Epitope Specificity
- Need: Distinguish between blocking IL-6 binding to IL6R (classical) vs blocking IL6R-IL6 complex binding to gp130 (allosteric).
- Assay: Ternary complex disruption assay using IL6, IL6R, and gp130.
- TarMart Advantage: Full panel of IL6, IL6R, and gp130 proteins for competitive binding studies.
Cross-Species Toxicology Bridge
- Need: Ensure cross-reactivity with cynomolgus IL6R for preclinical safety studies.
- Assay: Parallel binding assays with human and cyno IL6R.
- TarMart Advantage: Human and Cyno IL6R proteins with >98% sequence identity in binding domains.
High-Concentration Formulation
- Need: Subcutaneous formulations require >150 mg/mL with low viscosity and minimal aggregation.
- Assay: Accelerated aggregation (40°C, shaking) and rheometry.
- TarMart Advantage: Aggregation-tested ECD-Fc reference proteins with viscosity-compatible buffer recommendations.
Related Targets for Cross-Selling
Based on IL-6 signaling pathway biology, the following related targets are recommended for combination therapy studies or pathway validation:
-
IL6 (Interleukin-6)
- Rationale: Ligand-receptor direct interaction. Used for competition binding and pathway activation.
- Product Link: View IL6 Products
-
IL6ST (gp130 / CD130)
- Rationale: Signal-transducing subunit; IL6R must form a hexameric complex (IL6:IL6R:gp130 = 2:2:2) to activate JAK-STAT3 pathway.
- Product Link: View IL6ST Products
-
JAK1 (Janus Kinase 1)
- Rationale: Downstream kinase activated by IL6R. Used for combination therapy studies or to assess blockade of STAT3 phosphorylation.
- Product Link: View JAK1 Products
Product Specifications & Trust Factors
- Sequence Verified: Mass spec verification of ECD-Fc fusion protein amino acid sequence, ensuring correct D1-D2-D3 domains critical for IL-6 binding.
- Glycosylation Consistency: HEK293 expression system ensures correct N-glycosylation at Asn residues, affecting gp130 affinity.
- Endotoxin Control: All proteins <1 EU/µg, suitable for sensitive BaF3 cell proliferation assays.
- No Fake Data: Theoretical MW and SDS-PAGE purity clearly stated; no unvalidated bioactivity IC50 data provided. Tocilizumab positive control included as methodological validation tool.